Impact of HER2-low status on axillary response and surgical management after neoadjuvant chemotherapy in early breast cancer

被引：0
|
作者：
da Silva, Leonardo Roberto
Sartori, Guilherme
Ramalho, Susana
Reinert, Tomas
Da Rosa, Mahira Lopes
Tavares, Grazielle Morais
Mantovani, Higor
Vasconcelos, Vivian
Cabello, Ana Elisa Ribeiro Da Silva
Coelho, Guilherme
Mandelli, Jovana
Zaffaroni, Facundo
Barrios, Carlos
Graudenz, Marcia Silveira
Cabello, Cesar
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-17-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-17-12
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management
    Theresa Relation
    Samilia Obeng-Gyasi
    Oindrila Bhattacharyya
    Yaming Li
    Mariam F. Eskander
    Allan Tsung
    Bridget A. Oppong
    Annals of Surgical Oncology, 2021, 28 : 6489 - 6497
  • [22] An exploratory study of Trastuzumab Deruxtecan neoadjuvant therapy in HER2-positive or HER2-low early or locally advanced breast cancer after a poor response to neoadjuvant chemotherapy
    Zhang, Jin
    Shi, Zhendong
    Liu, Jingjing
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
    Domergue, Camille
    Martin, Elodie
    Lemarie, Camille
    Jezequel, Pascal
    Frenel, Jean-Sebastien
    Augereau, Paule
    Campone, Mario
    Patsouris, Anne
    CANCERS, 2022, 14 (10)
  • [24] HER2-low breast cancer and response to neoadjuvant chemotherapy: a population-based cohort study
    Baez-Navarro, Ximena
    van Bockstal, Mieke R.
    Jager, Agnes
    van Deurzen, Carolien H. M.
    PATHOLOGY, 2024, 56 (03) : 334 - 342
  • [25] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [26] Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
    Zhou, Shuling
    Liu, Ting
    Kuang, Xiaying
    Zhen, Tiantian
    Shi, Huijuan
    Lin, Ying
    Shao, Nan
    BREAST, 2023, 67 : 1 - 7
  • [27] Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
    Alves, Fatima R.
    Gil, Lucia
    de Matos, Leonor Vasconcelos
    Baleiras, Ana
    Vasques, Carolina
    Neves, Maria Teresa
    Ferreira, Andre
    Fontes-Sousa, Mario
    Miranda, Helena
    Martins, Ana
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
  • [28] The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes
    Cipolla, Calogero
    Lupo, Simona
    Grassi, Nello
    Battaglia, Maria cristina
    Mesi, Chiara
    Scandurra, Giuseppina
    Gebbia, Vittorio
    Valerio, Maria rosaria
    ANTICANCER RESEARCH, 2024, 44 (05) : 2047 - 2053
  • [29] Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
    Shi, Zhendong
    Liu, Yingxue
    Fang, Xuan
    Liu, Xu
    Meng, Jie
    Zhang, Jin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [30] Gene Mutation Spectrum in Luminal/HER2-low Early Breast Cancer after Neoadjuvant Chemotherapy: A Prospective, Multicenter Cohort Study
    Yang, Y.
    Chen, J.
    Zhu, Y.
    Gong, C.
    BREAST, 2025, 80
12345